TB alliance signs deal with Tibotec
This article was originally published in Scrip
Executive Summary
The TB Alliance, a public-private partnership, has signed a deal with the US anti-infectives firm Tibotec (Johnson & Johnson) over its investigational tuberculosis therapy, TMC207, which targets adenosine triphosphate synthase, required by Mycobacterium tuberculosis to generate energy.